Full Logo - OKYO .jpg
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
08 avr. 2024 19h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
02 avr. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
22 mars 2024 07h00 HE | OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
Full Logo - OKYO .jpg
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
21 mars 2024 07h00 HE | OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
Full Logo - OKYO .jpg
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20 mars 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09 févr. 2024 07h00 HE | OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
Full Logo - OKYO .jpg
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
31 janv. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
08 janv. 2024 07h00 HE | OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
Full Logo - OKYO .jpg
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
05 janv. 2024 09h30 HE | OKYO Pharma LTD
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
Full Logo - OKYO .jpg
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
04 déc. 2023 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...